Morbimortality of Covid-19 in Patients With Chronic Inflammatory Rheumatism Treated With Immunosuppressants (CORhum)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04426279|
Recruitment Status : Recruiting
First Posted : June 11, 2020
Last Update Posted : September 24, 2020
|Condition or disease||Intervention/treatment|
|Sars-CoV2 Rheumatoid Arthritis Rheumatic Diseases||Other: questionnaire assesment|
|Study Type :||Observational|
|Estimated Enrollment :||1500 participants|
|Official Title:||Morbimortality of Covid-19 in Patients With Chronic Inflammatory Rheumatism Treated With Immunosuppressants|
|Actual Study Start Date :||August 18, 2020|
|Estimated Primary Completion Date :||December 2020|
|Estimated Study Completion Date :||December 2020|
|patient with chronic inflammatory rheumatism||
Other: questionnaire assesment
15-minute face-to-face questionnaire
- analysis of Covid-19-related morbidity and mortality in patients with IRC under IS. [ Time Frame: At 6 months ]the number of patients with severe Covid-19 who were admitted to a conventional unit and/or an ICU and/or deceased, during the Covid-19 epidemic wave (from March to August 2020) among patients with IRC under IS. The diagnosis of Covid-19 is either confirmed by diagnostic test (RT-PCR), or by a physician, or by serology. The results will be compared with those of the general population based on Covid-19 epidemiological data.
- To evaluate the frequency of Covid-19 in patients with IRC under IS. [ Time Frame: At 6 months ]Diagnosis of Covid-19 either confirmed by diagnostic test (RT-PCR), or by a physician, or by serology.
- To compare the morbidity and mortality of patients with IRC under IS during the Covid-19 epidemic wave (March to August 2020) with the six months prior to this wave (September 2019 to February 2020). [ Time Frame: At 6 months ]The number of patients admitted to conventional unit and/or ICU and/or deceased among patients with IRC under IS between the Covid-19 epidemic wave (March to August 2020) and the six-month period preceding it (September to February 2020).
- Patients' conduct in relation to their treatment during the epidemic wave (maintenance, modification or discontinuation) and the impact on their disease (loss of remission, flare, corticosteroids requirement and need for switch of DMARD therapy) [ Time Frame: At 6 months ]The number of patients who maintained, modified, or discontinued their treatment. Treatment modification will be assessed by the number of weeks of treatment not taken, the number of injections not given, the number of delayed or missed infusions. Among those who have modified or stopped their treatment, the impact on their diseases will be evaluated by the loss of remission, the patient's opinion on the notion of relapse, the increase or initiation of corticosteroid therapy and the substantive change in treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04426279
|Contact: Jean-Guillaume Letarouilly, MD||0320446926 ext +email@example.com|
|Principal Investigator:||Jean-Guillaume Letarouilly, MD||University Hospital, Lille|